Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

106.45 +1.19 (+1.13%)

Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Via Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts

September 22, 2025

The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In...

Via MarketMinute

Topics Bonds ETFs Economy

Price Over Earnings Overview: Merck & Co ↗

September 22, 2025

Via Benzinga

FDA Clears Merck's One-Minute Cancer Shot ↗

September 22, 2025

FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September.

Via Benzinga

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff ↗

September 22, 2025

But that doesn't mean Keytruda is safe from the looming patent cliff.

Via Investor's Business Daily

Topics Intellectual Property

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

Via The Motley Fool

Topics Intellectual Property

Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda ↗

September 19, 2025

Via Stocktwits

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks? ↗

September 11, 2025

Via Stocktwits

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Via The Motley Fool

Topics Intellectual Property

FDA Approves Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Scores Positive Feedback From EU Agency Regarding Blockbuster Cancer Drug ↗

September 19, 2025

Merck received positive Keytruda notes from CHMP regarding its breakthrough cancer treatment with final decisions expected in late 2025.

Via Benzinga

Merck Reportedly Scraps Research Centre In UK: Retail Sees Stock Rallying To $97.50 ↗

September 10, 2025

Via Stocktwits

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Decoding Merck & Co's Options Activity: What's the Big Picture? ↗

September 19, 2025

Via Benzinga

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

September 19, 2025

From Merck & Co., Inc.

Via Business Wire

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?' ↗

September 18, 2025

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps,...

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots ↗

September 15, 2025

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices, just days...

Via Benzinga

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

Merck & Co. Inc. (NYSE:MRK): A Prime Value Stock with Strong Profitability and Sound Finances ↗

September 15, 2025

Discover Merck & Co. (MRK), a top value stock with strong profitability, sound financial health, and an attractive valuation. A prime pick for value investors.

Via Chartmill

Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

September 15, 2025

From Daiichi Sankyo

Via Business Wire

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

These drugmakers have competitive yields and have increased their dividends at a good clip.

Via The Motley Fool

Topics Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Excels in Caviar Cruise Quality Stock Screen ↗

September 13, 2025

Discover Merck & Co. (MRK), a top-tier stock excelling in profitability, high ROIC, strong cash flow, and a robust balance sheet for long-term quality investing.

Via Chartmill

Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs ↗

September 12, 2025

Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen.

Via Benzinga

Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data ↗

September 11, 2025

Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.

Via Benzinga

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease

September 11, 2025

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.